Project Grant R41CA302163
Award Date 9/12/25
Completion Date 8/31/26
Dollars Obligated $307K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $793,324 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme as a novel approach to treat hepatocellular carcinoma (HCC), including metabolic dysfunction-associated HCC. The project aims to discover and validate CYP8B1 inhibitors that may provide a unique pharmacological therapy for HCC, which is the...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $399,966 in funding to Cloverleaf Bio, Inc. to advance the pre-clinical development of a novel therapeutic approach for treating hepatocellular carcinoma (HCC), the most common form of liver cancer. The key objectives are to: (1) develop additional in vitro-optimized therapeutic transfer RNAs (tRNAs) containing the chemotherapeutic agent 5-fluorouracil (5-FU) to target multiple...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $687,679 aims to functionally characterize the transcriptional regulatory landscape of hepatocellular carcinoma (HCC) in order to uncover novel tumor cell-intrinsic vulnerabilities. The research plan involves computationally establishing human HCC transcriptional master regulators (TMRs), validating their tumor cell-intrinsic functions using CRISPR interference and activation...
- This Project Grant award of $402,400.00, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to explore myeloid-derived suppressor cells (MDSCs) as a therapeutic target for the treatment of hepatoblastoma (HB), a rare childhood liver cancer. The key goals are to determine which oncogenes drive the recruitment of PMN-MDSCs to HB tumors, and to test the effects of a CXCR2 inhibitor (SB225002) on HB tumor growth, both as a...
- This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $634,061 to the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment (TIME) of liver cancer or hepatocellular carcinoma (HCC) during HIV infection. The 5-year project aims to: 1) Characterize how TAPDC reprogram the HCC TIME in HCC-HIV mouse models and human samples; 2) Define how TAPDC modulate...
- This $421,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research to investigate how the LIFR-LCN2 pathway in liver cancer restricts the cytotoxic function of CD8+ T cells, leading to immune evasion and resistance to immunotherapy. The central hypothesis is that loss of LIFR upregulates LCN2 in liver cancer, thereby suppressing the abundance and cytotoxic function of CD8+...
- This $104,096 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) supports an integrated in silico and in vivo genetic screening approach to identify subtype-specific genetic dependencies for hepatocellular carcinoma (HCC). The award was made to the University of Pittsburgh and aims to determine if genetic dependencies predicted via deep learning demonstrate subtype specificity using in vivo loss-of-function screening, and to quantify...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, supports research to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma (liver cancer). The $470,759 award, commencing on September 1, 2025, aims to prevent CAR T-cell exhaustion and improve the antitumor activity of GPC3-CAR T-cells through the precise, on-demand control...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...